Barclays initiates Zurn Water Solutions stock at overweight

Barclays initiated coverage on Zurn Water Solutions (ZWS) with an Overweight rating and a $59 price target, citing ~10% EBITDA per share growth potential and improving non-residential construction water recovery tailwinds into 2027–28. The stock has returned 37.7% over the past year but is flagged as potentially overvalued versus fair value (P/E 40.73). Separately, Zurn Elkay reported Q1 2026 EPS of $0.41 vs $0.36 consensus and revenue of $433M vs $418.99M forecast (11% organic growth), while a quarterly cash dividend of $0.11/share was declared (payable June 5, 2026).

Analysis

ZWS is increasingly being treated as a “quality cyclicals” story rather than a pure nonres construction beta. The key mechanism is mix shift: retrofit, replacement filters, and installed-base monetization can support mid-single to low-double-digit earnings growth even if new construction remains choppy, which justifies a premium multiple relative to more project-heavy peers. That said, at ~40x earnings, the stock already discounts several years of clean execution; the market is paying for durability, not just a cyclical rebound.

The second-order implication is rotation within building products: investors may favor names with recurring revenue and less municipal or federal budget dependence, while punishing suppliers that only benefit from one-off capex. If ZWS keeps comping well, the next leg is likely driven less by estimate raises and more by capital returns plus M&A optionality; that can widen the gap versus lower-quality construction names over the next 1-3 quarters. The risk is that the nonres recovery itself is late-cycle: if rates stay higher for longer or institutional construction rolls over, the valuation support disappears faster than the earnings model.

Contrarian read: consensus may be over-crediting 2027-28 visibility when the nearer-term issue is whether current growth can stay above high-single digits without margin giveback. The stock likely needs either another guide-up or evidence that recurring replacement revenue is large enough to flatten the cycle; otherwise the upside is capped by multiple compression even if fundamentals remain decent. For now, this looks more like a hold-the-line quality name than an obvious fresh long after a strong run.

Key Decisions for Investors

• Do not chase ZWS at current levels; wait for a 5-8% pullback or a softer tape in construction beta before initiating. The risk/reward is better on entry than on momentum.
• If already long, hedge valuation risk with a call spread overwrite or reduce gross into any post-earnings strength; the main downside is multiple compression, not near-term earnings collapse.
• Pair trade idea: long ZWS / short ITB or XHB for a 1-3 month relative-value bet that recurring retrofit exposure outperforms pure new-build beta if nonres construction data softens.
• Watch the next earnings call for organic growth and margin bridge; if organic growth drops below high-single digits or EBITDA-per-share growth guidance falls under ~10%, the thesis weakens materially.
• Alert on any M&A announcement or accelerated buyback authorization: that is the cleanest catalyst for another leg higher, because it would convert operational strength into per-share acceleration.